India’s drug regulatory body to create new database to monitor drug manufacturers

Indian flag
India's Central Drugs Standard Control Organization is creating a national digital database of pharmaceutical manufacturers and their medicines to help address drug shortages and quality issues. (Yann Forget/Wikimedia Commons)

The Central Drugs Standard Control Organization, India’s drug regulatory body, said it will create a national digital database of pharmaceutical manufacturers and their medicines to help address drug shortages and quality issues.

The regulatory agency told the Economic Times it is in the process of finalizing the software to be used for the database and will amend its rules and regulations to make it mandatory for manufacturers to regularly put details of their facilities and products into the database.

India does not have a comprehensive, real-time information database on drugmakers in the country. The regulatory agency currently relies on information gathered by state authorities, who often don’t know what drugs are produced in other states.

“Now, there is going to be a completely transparent system with proper data management,” a senior government official, who was not identified, told the newspaper.

The software system is expected to be ready and will be discussed at a meeting of the agency and state drug regulators next week.

Indian drugmakers have been a particular target of the FDA and European Medicines Agency in the past few years. Those agencies have cited—and in some cases banned—a number of manufacturers for violations that span the range from vermin in factories to sloppy or falsified record keeping.

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

A Chinese company's producing a remdesivir generic. Daiichi expects $18 million in Enhertu Q1 sales. Tecentriq becomes seventh PD-1/L1 to enter China.